Regeneron Pharmaceuticals Inc (REGN)
Return on equity (ROE)
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net income (ttm) | US$ in thousands | 3,953,600 | 3,991,100 | 4,299,000 | 4,182,700 | 4,338,400 | 5,370,300 | 5,686,800 | 7,933,600 | 8,075,300 | 6,995,500 | 6,205,400 | 4,003,800 | 3,513,200 | 3,156,000 | 2,983,500 | 2,279,300 | 2,115,800 | 2,144,200 | 2,069,300 | 2,427,600 |
Total stockholders’ equity | US$ in thousands | 25,973,100 | 24,904,400 | 24,017,900 | 23,495,200 | 22,664,000 | 21,438,800 | 20,687,800 | 19,914,700 | 18,768,800 | 17,258,000 | 15,127,300 | 11,977,000 | 11,025,300 | 10,125,500 | 9,057,400 | 12,133,000 | 11,089,700 | 10,504,400 | 9,755,900 | 9,444,700 |
ROE | 15.22% | 16.03% | 17.90% | 17.80% | 19.14% | 25.05% | 27.49% | 39.84% | 43.03% | 40.53% | 41.02% | 33.43% | 31.86% | 31.17% | 32.94% | 18.79% | 19.08% | 20.41% | 21.21% | 25.70% |
December 31, 2023 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $3,953,600K ÷ $25,973,100K
= 15.22%
Regeneron Pharmaceuticals, Inc.'s return on equity (ROE) showed a decreasing trend over the past eight quarters, with the ROE declining from 39.84% in Q1 2022 to 15.22% in Q4 2023. This suggests that the company's profitability in generating returns from shareholders' equity has been gradually decreasing over this period. The significant drop in ROE from Q2 2022 (27.49%) to Q3 2022 (25.05%) may warrant further investigation into the factors contributing to this decline.
A declining ROE could indicate decreasing efficiency in utilizing equity to generate profits or declining profitability relative to equity investments. Investors and analysts may want to assess the company's financial strategy, operational performance, and capital structure to understand the reasons behind this trend and evaluate the sustainability of Regeneron Pharmaceuticals, Inc.'s financial performance.
Peer comparison
Dec 31, 2023
See also:
Regeneron Pharmaceuticals Inc Return on Equity (ROE) (Quarterly Data)